Login / Signup

Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.

Takayuki TakedaMayumi TakeuchiMasahiko SaitohSorou Takeda
Published in: Thoracic cancer (2018)
Clarifying NLR four weeks after nivolumab administration may be useful to predict outcomes in nivolumab-treated patients.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • gestational age
  • patient reported outcomes